Sofosbuvir/daclatasvir
Sofosbuvir/Daclatasvir[edit]
Sofosbuvir/Daclatasvir is a combination of two antiviral medications used in the treatment of hepatitis C. This combination is effective against multiple genotypes of the hepatitis C virus (HCV) and is often used in patients with chronic HCV infection.
Mechanism of Action[edit]
Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, which is essential for viral replication. By inhibiting this enzyme, sofosbuvir prevents the virus from multiplying within the host cells.
Daclatasvir is an inhibitor of the HCV NS5A protein, which plays a crucial role in viral replication and assembly. By targeting NS5A, daclatasvir disrupts the replication cycle of the virus.
Indications[edit]
The combination of sofosbuvir and daclatasvir is indicated for the treatment of chronic hepatitis C infection in adults. It is effective against multiple HCV genotypes, including genotypes 1, 2, 3, and 4.
Dosage and Administration[edit]
The typical dosage of sofosbuvir/daclatasvir is one tablet taken orally once daily. The duration of treatment can vary depending on the genotype of the virus and the presence of cirrhosis or other liver conditions.
Side Effects[edit]
Common side effects of sofosbuvir/daclatasvir include fatigue, headache, nausea, and insomnia. Most side effects are mild and manageable.
Drug Interactions[edit]
Sofosbuvir/daclatasvir can interact with other medications, including certain antacids, anticonvulsants, and antiretrovirals. It is important to review all medications with a healthcare provider to avoid potential interactions.
